Aileron Therapeutics (NASDAQ:ALRN) Announces Quarterly Earnings Results, Misses Estimates By $0.72 EPS

Aileron Therapeutics (NASDAQ:ALRN) announced its quarterly earnings data on Monday. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.72), Zacks reports.

Aileron Therapeutics Stock Down 1.9 %

Shares of ALRN traded down $0.07 during trading hours on Wednesday, reaching $3.70. 6,496 shares of the company traded hands, compared to its average volume of 73,783. Aileron Therapeutics has a 12 month low of $1.01 and a 12 month high of $7.42. The company has a market capitalization of $79.88 million, a price-to-earnings ratio of -1.16 and a beta of 2.32. The company’s fifty day moving average price is $5.04 and its two-hundred day moving average price is $4.09.

Insiders Place Their Bets

In other Aileron Therapeutics news, major shareholder Of Texas/Texas Am I. University sold 10,746 shares of the firm’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $4.95, for a total transaction of $53,192.70. Following the completion of the transaction, the insider now owns 1,799,711 shares of the company’s stock, valued at $8,908,569.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $4.21, for a total value of $85,526.15. Following the completion of the transaction, the insider now owns 1,779,306 shares in the company, valued at $7,490,878.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Of Texas/Texas Am I. University sold 10,746 shares of the company’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $4.95, for a total value of $53,192.70. Following the transaction, the insider now directly owns 1,799,711 shares in the company, valued at $8,908,569.45. The disclosure for this sale can be found here. 5.57% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH raised their price target on shares of Aileron Therapeutics from $9.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, April 18th.

About Aileron Therapeutics

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.